Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Acanthosis nigricans

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise the velvety flexural phenotype, investigate common metabolic and endocrine drivers without stigma, and identify the rare sudden extensive pattern that can signal internal malignancy.

  • Acanthosis nigricans is velvety thickened hyperpigmented skin, usually on the posterior neck, axillae or groins; texture and distribution are more diagnostic than colour alone.
  • Insulin resistance associated with higher adiposity, type 2 diabetes or polycystic ovary syndrome is the commonest acquired context, but the sign is not itself a glucose diagnosis.
  • Examine respectfully in good light and ask permission before folds are exposed; in dark skin the change may be prominent, but baseline pigmentation must not be pathologised.
  • Check blood pressure and metabolic risk, then use HbA1c or glucose testing through the appropriate diabetes pathway rather than assuming normality or disease from appearance.
  • Irregular cycles, hirsutism or fertility concerns support a PCOS assessment, while hypothyroid, Cushing or medicine testing should follow specific clinical clues.
  • Sudden extensive itchy disease, mucosal papillomatosis, tripe palms and unexplained weight loss are uncommon but important malignant-acanthosis features.
  • Treating the driver may soften and lighten skin gradually; weight-management support should be person-centred and never framed as blame or a guaranteed cosmetic cure.
  • Keratolytics and retinoids offer inconsistent cosmetic benefit and can irritate folds, so underlying risk reduction and realistic expectations remain central.

Key red flags

Abrupt rapidly progressive acanthosis in an older adult, especially with weight loss, marked itch, mucosal involvement, tripe palms or no metabolic explanation, requires expedited investigation for an internal malignancy.

Malignant-pattern warning

Rapid widespread itch, mucosal papillomatosis, tripe-like palms and weight loss in an older person demand expedited systemic assessment.

Investigation priorities

01
HbA1c or fasting plasma glucoseFirst step

Detect prediabetes or type 2 diabetes in a metabolically plausible phenotype.

Management branches

Typical metabolic patternMeasure risk without making assumptions

Stable flexural acanthosis occurs with plausible insulin resistance and no malignant warning features.

  1. Confirm velvety thickening by examination, document onset and family tendency, and ask about cycles, hair change, medicines, sleep and symptoms of hyperglycaemia.
  2. Measure blood pressure and arrange HbA1c or fasting glucose plus lipids and other cardiovascular assessment according to age and risk.
  3. Offer person-centred nutrition, activity and weight support where wanted, and treat diagnosed diabetes, hypertension, dyslipidaemia or PCOS through their own evidence-based pathways.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • Primary Care Dermatology Society acanthosis nigricansClinical phenotype, associations, malignant warning features and management.
  • NICE NG28 type 2 diabetes recommendationsDiagnosis and management of dysglycaemia associated with insulin resistance.
  • NICE NG246 overweight and obesity recommendationsPerson-centred assessment and non-stigmatising weight-management pathways.
  • NHS type 2 diabetesSymptoms, diagnosis, prevention and long-term risk communication.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom